Kornimate/medical-research-clean huggingface dataset:
metabolomics profiling of coronary heart disease

Conditions: Biomarkers

Summary: this study sought to assess the diagnostic and prognostic values of metabolomics in coronary artery disease(cad).

the purpose of this study is to establish a powerful diagnostic and prognostic model based on metabolites in cad patients.a total of 821 hospitalized patients with cad and 200 healthy volunteers are enrolled.specifically, 200 cad patients from single-centre are regarded as discovery set, 300 cad patients from multicentre are regarded as validation set. a third independent set including 321patitents is regarded as application set. untargeted and targeted metabolomics analysis about serum and urine samples in all subjects will be performed using high-performance liquid chromatography coupled with mass spectrometry technology. univariate and multivariate analysis methods are used to extract and analyze the differential mebabolites. by exploring the relationship between the differential mebabolites and clinical manifestions, a set of diagnostic biomarkers for cad will be identified. by elucidating the correlation between the differential mebabolites and maces, a effective prognostic model will be established. adverse events are defined as the combined endpoints of death or major adverse cardiovascular events(maces) in patients with cad for at least 1 year follow-up after discharge. in brief, we aim to establish valuabe diagnostic and predictive models based on novel baseline metabolites in patients with cad.

Eligibility criteria:
inclusion criteria: * objective evidence of coronary heart disease risk factors * or angina pectoris symptoms * or ecg ischemic changes * or elevated myocardial enzymes, myocardial radionuclide scanning showing myocardial filling defect, coronary ct showing coronary stenosis ≥ 50% exclusion criteria: * older than 80 years and younger than 18 years old, * aortic dissection * pulmonary embolism * malignant tumor * autoimmune diseases * systemic systemic diseases * severe infectious diseases * trauma, surgery in the last three months * myocarditis, cardiomyopathy, pericarditis, severe congenital heart disease * syphilis * human immunodeficiency virus / acquired immunodeficiency syndrome * hepatitis b and hepatitis c

Keywords: metabolomics biomarkers liquid chromatography-mass spectrometry coronary artery disease serum urine
a study of abemaciclib (ly2835219) in participants with previously treated kras mutated lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: the main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.


Eligibility criteria:
inclusion criteria: * have confirmed diagnosis of stage iv non-small cell lung cancer (nsclc) according to the american joint committee on cancer staging handbook. * determined to have detectable mutations in codons 12 or 13 of the kirsten rat sarcoma (kras) oncogene by an investigational assay at the study central laboratory. a kras positive mutation result in codons 12 or 13 of the kras oncogene from tumor tissue per local laboratory will be permitted in no more than 10% of randomized participants. * have progressed after platinum-based chemotherapy (with or without maintenance therapy) and have received one additional therapy which may include an immune checkpoint inhibitor or other anti-cancer therapy for advanced and/or metastatic disease or is judged by the physician as ineligible for further standard second-line chemotherapy. participants who have progressed after platinum-based chemotherapy and an immune checkpoint inhibitor (immunotherapy) e.g. pembrolizumab or nivolumab alone or in combination with other agents are eligible. * have measureable disease as defined by the response evaluation criteria in solid tumors (recist 1.1). * have a performance status (ps) of 0 to 1 on the eastern cooperative oncology group (ecog) scale. * have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug. exclusion criteria: * have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively. * have a personal history of any of the following conditions: presyncope or syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. * have the presence of unstable central nervous system (cns) metastasis. history of cns metastasis or stable cns metastases is allowed (no longer requiring active therapy such as steroid medications). participants with a history of cns metastases must have a brain scan (for example, magnetic resonance imaging \[mri\]) within 28 days of randomization to document stability, even if there have been no changes in symptoms. * have previously completed or withdrawn from this study or any other study investigating a cyclin-dependent kinase 4 (cdk4) and cyclin-dependent kinase 6 (cdk6) inhibitors, or have received treatment with a prior cdk4 and cdk6 inhibitors.

Keywords: therapy, platinum, kras +
effects of two different applications in fibromyalgia

Conditions: Fibromyalgia

Summary: the study aims to determine the effect of connective tissue massage and taping applications on the pain and depression complaints of fibromyalgia patients and to compare their impact on quality of life.


Eligibility criteria:
inclusion criteria: * being diagnosed with fibromyalgia. * be in the age range of 20 - 55 years. * to be a volunteer participant in the research. * being able to communicate comfortably. * to be able to act independently. exclusion criteria: * having had a surgical operation within the last year. * presence of significant infection. * being diagnosed with cancer. * being pregnant or breastfeeding. * being addicted to drugs or alcohol. * having a cognitive problem.
cervical exercise in peripheral vestibular disorders

Conditions: Vestibular Disorder; Peripheral Vestibular Disorder

Summary: 70 patients with peripheral vestibular disorders will be included in the study. half of the subjects will receive vestibular rehabilitation exercises and the other half will receive additional cervical exercises. results from the two groups will be compared.

70 patients with a diagnosis of peripheral vestibular disease will be enrolled in the study. patient selection will be carried out in the physiatry, otorhinolaryngology and neurology outpatient clinics of our university hospital. eligible patients will be informed about the study and those that accept to take part in the study will be referred to an investigator for history taking and physical examination. demographic data, medical history and examination findings will be recorded. after initial assessment, all patients will receive a short education regarding vestibular exercises that they will be asked to do at home. a second investigator will be responsible for the randomization of subjects into two groups according to a computer generated randomization table and that same investigator will prescribe the second group additional cervical exercises to do in addition to the vestibular rehabilitation exercises. after one months, patients will be reassessed and their measurements will be recorded. statistical analyses will be carried out to compare the outcome scores of the two groups.

Eligibility criteria:
inclusion criteria: * a diagnosis of peripheral vestibular disease * being older than 18 years of age exclusion criteria: * psychostimulant or psychotropic drug use that might alter vestibular functions * severe neurological, psychiatric or orthopedic disorder that might alter patients' ability to comply with the exercise program.

Keywords: vestibular disorders cervical exercises vertigo vestibular exercises
therapeutic effect of the natural mineral water of the well b-308 okk in győr (gyirmót) on knee osteoarthrosis

Conditions: Knee Osteoarthritis

Summary: the main purpose of the study is to investigate the therapeutic effect of the thermal water of győr (gyirmót) well no. b-308 okk on patients with knee arthrosis, and to compare its therapeutic effect with tap water (placebo) group.

after being informed about the study and the potential risks, all patients giving written informed consent will undergo a continuous screening period, until the number of 25-25 patients is reached, to determine eligibility for study entry. at week 0, patients who meet the eligibility requirements will be randomized in a double-blind manner in a 1:1 ratio to medicinal water or placebo group.

Eligibility criteria:
inclusion criteria: * knee osteoarthrosis that has existed for at least 3 months * age between 50 and 80 years * willingness to participate in 3-week outpatient rehabilitation treatment * pain in the knee joint lasting at least 3 months and at least 5 days a week * at least mild pain during selection (1 point on the likert scale) * does not have a serious disability exclusion criteria: * any kind of physiotherapy treatment in the last 2 months (except home gymnastics) * any previous knee joint surgery * any trauma to the knee or hip joint in the 1 year prior to the examination * knee arthroscopy performed within 3 months prior to the examination * intra-articular corticosteroid treatment of the affected knee in the last 3 months * palpable baker's cyst * any hip joint or spine surgery within a year before the examination * intra-articular hyaluronic injection within 2 months before the examination * appearance of lumbar radiculopathy * presence of serious internal medicine disease, urogenital or other diseases * uncooperative or psychoneurotic patients * lumbago, sciatica; and any other surgery or previous fracture in the hip joint * subluxation, luxation, algodystrophy, fibromyalgia, gout * balneotherapy in the last 6 months * systemic corticosteroid treatment in 1 month before the examination * starting the treatment of osteoarthritis sysadoa (symptomatic slow-acting drugs for osteoarthritis) in 3 months before the examination

Keywords: medicinal water healing water balneotherapy womac
nasal xylitol in the prevention of otitis media

Conditions: Otitis Media

Summary: acute otitis media (aom) is one of the most prevalent and costly illnesses in children throughout the world. aom can lead to chronic otitis media with effusion (ome) resulting in conductive hearing loss that can cause speech, language, academic, and social developmental delays. complementary and alternative medicines are being widely used for prevention of aom. xylitol is a five carbon polyol (sugar alcohol) produced from natural plants and is used for preventing dental caries and aom in children. it is commercially available in chewing gums, syrups and toothpastes washes, and other products. xylitol was shown in several studies to prevent the culture of bacteria in the nasopharynx and oral cavity. it was proven to eliminate the ability of bacteria to attach to the mucosa of the upper respiratory system. it was proven to reduce the ability of bacteria to attach to the mucosa of the upper respiratory system. previous study had shown that oral usage of xylitol (as chewing gum or syrup) can reduce the incidence of raom by 30% as compared to placebo. but this treatment did not gain popularity since the initial clinical trial 30 years. there are several potential reasons for that. first, xylitol should be administrated 5 times daily in order to be effective. study that checked usage of oral xylitol 3 times daily in children with raom did not find additional advantage as compared to placebo. secondly, by using xylitol orally we rely on the gut absorption and systemic distribution. xylitol absorbs poorly in the gut and can cause some gi symptoms (like nausea and diarrhea) especially when used in a syrup (the preferred way in small children). in this study the investigators aim to test the yield of xylitol nasal spray as a preventive treatment in children with raom. by using xylitol as nasal spray we deliver the active compound directly to the action site (nasopharynx- the aom reservoir) and avoid the gi side effects


Eligibility criteria:
inclusion criteria: 1. children at the age of 1-5 years that suffered from recurrent otitis media (3 episodes in the last 6 months prior to entrance to the study) exclusion criteria: 1. children with immune deficiency 2. children with craniofacial malformations 3. children with chronic otitis media 4. children that received prophylactic antibiotic treatment prior to entering the study (3 months )
treatment result of zirconia laminate veneer

Conditions: Dislocation, Tooth; Teeth, Endodontically-Treated; Tooth Fracture; Tooth Injuries; Tooth Abnormalities; Cracked Tooth Syndrome; Tooth Crowding

Summary: this study aims to evaluate the clinical performance of the zirconia laminate veneer, a minimally invasive prosthetic restoration

patients with indications for single tooth restoration with ceramic laminate veneers are recruited for the study. these indications include spaced, discolored, malformed, root canal-treated, chipped, and mildly crowded teeth. after providing written informed consent, all patients are randomly divided into two groups in a double-blind manner (participants and the outcomes assessor) in a 1:1 ratio, including the zirconia group (intervention) and the lithium disilicate group (control). each patient's tooth is prepared and restored with the corresponding laminate veneer material, that is, zirconia and lithium disilicate.

Eligibility criteria:
inclusion criteria: * spaced tooth * discolored tooth * malformed tooth * root canal-treated tooth * chipped tooth * mildly crowded tooth exclusion criteria: * tooth bruxism * inadequate enamel for bonding * large restoration exists * bad oral habits harming restoration

Keywords: ceramic laminate veneers zirconia lithium disilicate computer-aided manufacturing
vr headset for pain during pregnancy termination

Conditions: Pregnancy Termination

Summary: the goal of this randomized control study is to see if virtual reality headsets (vrhs) are useful in women undergoing surgical pregnancy termination. the main questions it aims to answer are: do vrhs decrease the pain associated with surgical pregnancy termination participants will wear the vrhs during the surgery and take a pain survey before and after the procedure. the pain assessment will be compared to placebo headset which will be randomly assigned.

use of virtual reality headsets have been employed in cancer and behavioral medicine fields with moderate success in controlling anxiety stress and pain. the decision to terminate a pregnancy can create significant stress and anxiety. in the us, there are over 900,000 pregnancy terminations each year with many patients undergoing dilation and evacuation with minimal anesthesia. we plan to assess virtual reality headset's ability to decrease pain associated with surgical termination of pregnancy. patient's will be recruited from a single outpatient family-planning center. inclusion criteria include all patients over the age of 18 that are undergoing a surgical termination of pregnancy in the first and second trimester under local and/or conscious sedation anesthesia. patients under the age of 18 with significant medical comorbidities will be excluded. patient demographics including age, bmi, obstetric/ gynecology history, and prior terminations will be collected. patients will be given pre- procedure survey to assess anxiety and stress. the survey will be self-administered with assistance from study personnel. patients will then be randomized to either the virtual reality headset or no headset. the procedure will be then performed with the headsets on the patients. amount and type of local anesthesia employed will be recorded. after the procedure (within 1 hour), the individuals will be resurveyed for both stress and anxiety, with the addition of a visual analog scale to assessing pain associated with the procedure. pre and post vital signs will also be extracted from the chart. the patient as well as the clinician performing the procedure will be masked as to the intervention. we will require 50 patients per arm assuming a 30% reduction in the pain scale (power 80%, 95% ci, with sd of 0.70). logistic regression will be performed for those comorbidities that may be influence our outcome, such as age, bmi, prior terminations.

Eligibility criteria:
inclusion criteria: * all healthy patients undergoing a first or second trimester pregnancy termination exclusion criteria: * pregnancy patients requesting a termination under the age of 18
effect of budesonide on exhaled nitric oxide in asthmatic children

Conditions: Asthma

Summary: to study the improvement in airway inflammation in children with asthma non-invasively with exhaled breath no, a marker of inflammation, after therapy with nebulized budesonide as 0.5mg daily.

comparisons will be made before and after 2 week therapy of nebulized budesonide in children not on prior anti-inflammatory medications.

Eligibility criteria:
inclusion criteria: * asthma diagnosis previously for 6 months * past asthma medication without change for previous 6 months * increased no levels and ability to perform maneuver * icf signed by parents exclusion criteria: * systemic steroids in past 60 days,inhaled/nebulized steroids in past 4 weeks * hospitalization within 3 months * upper or lower airways active infection or cigarette smoke direct exposure * use of other asthma medications other than bronchodilators one month prior and during the trial * noncompliance
could physical activity help to counteract the blood haemophilia disturbance? a pilot study.

Conditions: Hemophilia A

Summary: physical activity is lower in patients with haemophilia than in their healthy peers. nevertheless, exercize is recommended for those patients and supported by evidence. until 2013, scientific and medical evidence to encourage physical activity for patients with haemophilia were listed to increase their locomotor function, their metabolic status, their fitness level and their well-being. in 2013, an original publication by groen et al. suggested that physical activity could also interact with the specific and biological disturbance of the disease. we propose to consider that regular endurance exercize prescription should be encouraged in patients with haemophilia not only for a healthier lifestyle but also because it could positively alter the specific biological blood disturbance seen in haemophilia. nevertheless, before planning a well powered intervention trial we need to determine the acceptability of regular exercize and the expected value of factor factor viii, von willebrand factor and von willebrand propeptide after an endurance training program.


Eligibility criteria:
inclusion criteria: * mild (fviii:1-5%) and moderate (fviii:6-40%) haemophilia a patients, * living in the midi-pyrenees region, * between 18 and 45 years old, * exempt from any significant medical condition that could prevent them from being subjected to an endurance training program, * affiliated to a social security cover exclusion criteria: * women * subjects declaring 2 or more spontaneous bleeding events and/or 4 or more induced bleeding events out of a traumatic circumstance 6 months prior to inclusion * absence of signed consent * patient protected by justice

Keywords: training program endurance von willebrand factor
randomized trial of interventions to improve warfarin adherence

Conditions: Atrial Fibrillation; Deep Vein Thrombosis; Dilated Cardiomyopathies

Summary: the purpose of this research study is to see if a lottery which provides the opportunity to win money, a reminder system using a "med-emonitor", or the combination of both might be useful in helping patients to achieve better control of their anticoagulation therapy. selection for the arms of the study is randomized by the study computer. some will participate in the daily lottery only, some with the reminder system only, some with the reminder system and the daily lottery, and some with neither the lottery nor the reminder system.

eligible subjects will be enrolled in one of the 4 arms of the rct and followed for 6 months, with the primary outcome of out-of-range inrs. subjects will be given a med-emonitor to connect to their home phone line. for all subjects, these will be used to measure daily adherence. subjects in the incentive group will be eligible for a daily lottery prize only if, prior to the lottery being resolved, their adherence device has registered adherence to their prescribed warfarin regimen. subjects in the mm group will have the reminder/feedback features of the med-emonitor turned on to provide reminders to take their warfarin as prescribed and standardized messages that will be used to provide feedback in response to their adherence. subjects in the combined group will be exposed to both the lottery and the activated med-emonitor. this trial is a randomized controlled trial. both men and women who are at least 18 years of age and have been prescribed anticoagulation medication are eligible to participate.

Eligibility criteria:
key inclusion criteria the study population will include all patients at the study sites who: 1. are in the maintenance phase of their warfarin treatment (defined using the standard method as the period of time following 2 consecutive visits, at least 7 days apart, of stable target inr after initiation of the drug) 2. whose providers indicate are expected to stay on treatment for at least 6 months 3. have a target inr of 2 to 3.5 4. had at least one inr out of the participant's target range within 90 days prior to enrollment (excluding the baseline visit) and/or inr at the baseline visit was below the participant's target range 5. have a working analog telephone line. of note, patients do not have to be within their target inr range to enroll; we specifically want to include those who are below the target range at the time of study entry because they may be the patients most likely to be non-adherent. key exclusion criteria patients will be excluded if they do not meet the above inclusion criteria, 1. have an inr at screening above the target range 2. are less than 18 years of age and cannot or will not give consent 3. cannot read above a 6th grade reading level 4. are enrolled in a clinical trial of warfarin therapy 5. are unable to adequately follow study procedures

Keywords: warfarin coumadin adherence mechanical heart valves
psychological impact of amenorrhea in women with endometriosis

Conditions: Amenorrhea; Endometriosis; Quality of Life

Summary: the purpose of the study is to evaluate the impact on quality of life, psychological health, sexuality and chronic pain of therapies which determine amenorrhea in symptomatic women with endometriosis, through the administration of self reported questionnaires. amenorrhea in the first group is caused by balanced assumption of estroprogestins, in the second group is caused by gnrha-induced hypoestrogenism.


Eligibility criteria:
inclusion criteria: * clinical, echographical or surgical diagnosis of endometriosis exclusion criteria: * comorbidity * psychiatric diseases * refusal or inability to sign informed consent